Polycythemia Vera (Crisis)MANAGEMENT

HEMATOLOGIC AND ONCOLOGIC PRESENTATIONS · 12 SECTIONS

⚲

660 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Acute chest syndrome Acute Hemolytic Transfusion Reaction Anticoagulant reversal (warfarin, DOAC, heparin)Aplastic Anemia (Crisis)Autoimmune Hemolytic Anemia CAR-T and cytokine release syndrome Coagulopathy Delayed Hemolytic Transfusion Reaction Disseminated Intravascular Coagulation (DIC)Essential Thrombocythemia Febrile Non-hemolytic Transfusion Reaction Graft Versus Host Disease (Acute)Hemolytic Uremic Syndrome (HUS)Hemophilia A (Bleeding Crisis)Heparin-Induced Thrombocytopenia (HIT)Hyperviscosity syndrome Immune checkpoint inhibitor toxicity Immune Thrombocytopenic Purpura (ITP)Leukemoid Reaction Leukostasis Massive transfusion protocol Myelofibrosis Neutropenic enterocolitis (typhlitis)Paroxysmal Nocturnal Hemoglobinuria Polycythemia Vera (Crisis)Pure Red Cell Aplasia Sickle Cell (Acute Chest Syndrome)Sickle Cell (Splenic Sequestration)Sickle cell crisis (vaso-occlusive)Symptomatic anemia Thrombocytopenia (severe)Thrombotic Thrombocytopenic Purpura (TTP)Transfusion-Associated Circulatory Overload (TACO)Transfusion-Related Acute Lung Injury (TRALI)Tumor lysis syndrome Von Willebrand Disease (Bleeding)

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp49

Immediate priorities

›Thrombotic emergency recognition

›Acute stroke presentation

›Sudden focal weakness, aphasia, visual loss

›Activate stroke pathway if within treatment window

›Acute coronary syndrome

›Chest pain, diaphoresis — ACS occurs in ~8.3% of PV patients

›Immediate ECG and troponin

›Pulmonary embolism

›Acute dyspnea, pleuritic chest pain, hypoxia

›PE in approximately 2% of PV presentations

›Splanchnic vein thrombosis

›Acute abdominal pain, ascites, hepatomegaly — Budd-Chiari pattern

›PV suspected in any young patient with unprovoked splanchnic thrombosis

›Cerebral venous sinus thrombosis

›Severe headache, papilledema, seizures

›MRI/MRV brain required for diagnosis

Hemodynamic and hematologic stabilization

›Critical hematocrit threshold

›Hematocrit target below 45% — CYTO-PV trial primary endpoint

›Hematocrit above 45% doubles cardiovascular mortality and thrombosis

›Urgent therapeutic phlebotomy when hematocrit critically elevated

›Therapeutic phlebotomy protocol

›Remove 400 to 500 mL whole blood per session

›Repeat every 1 to 3 days until hematocrit below 45%

›Replace with normal saline volume for volume-sensitive patients

›Hyperviscosity syndrome management

›Hyperviscosity features

02History/hx66

Presenting symptoms

›Hyperviscosity symptoms

›Headache

›Diffuse, pressure-like

›Exacerbated by elevation in hematocrit

›Visual disturbance

›Blurring, scotomata, transient visual loss

›Fundoscopic engorgement of retinal veins

›Neurologic

›Dizziness, tinnitus, fatigue

›Focal deficits — stroke or TIA

›Thrombotic symptoms

›Cardiovascular

›Chest pain, dyspnea — ACS or PE

›Claudication — peripheral arterial thrombosis

›Abdominal

›Acute abdominal pain, ascites — splanchnic vein thrombosis

›Right upper quadrant pain — Budd-Chiari hepatic vein occlusion

›Dermatologic and vasomotor symptoms

›Aquagenic pruritus

›Present in approximately 33% of PV patients

›Triggered by contact with water of any temperature

›Erythromelalgia

›Burning pain, erythema, and warmth in digits or feet

›Responds to aspirin

PV disease context

›Known diagnosis history

›Duration of PV diagnosis

03Physical Exam/exam48

Vital signs

›Hemodynamic snapshot

›Blood pressure

›Hypertension common in PV — contributes to thrombotic risk

›Hypotension — major hemorrhage or sepsis

›Heart rate

›Tachycardia — PE, ACS, or volume depletion

›Oxygen saturation

›Hypoxia — PE, pulmonary hypertension, or severe anemia if bleeding

›Temperature

›Fever — infection or leukemic transformation concern

General and skin exam

›Classic PV appearance

›Plethoric facies

›Ruddy, flushed facial complexion from erythrocytosis

›Conjunctival injection

›Engorgement visible in conjunctival vessels

›Cyanosis

›Peripheral cyanosis in advanced hyperviscosity

›Skin findings

›Aquagenic scratch marks

›Excoriations from chronic pruritus

›Erythromelalgia

›Erythema, warmth, and swelling of digits

›Ecchymoses and petechiae

›Bleeding from AvWS or anticoagulation

Abdominal and organ exam

›Splenomegaly

04Differential Diagnosis/ddx40

Erythrocytosis mimics

›Secondary erythrocytosis

›ICD-10 D75.1

›Chronic hypoxia: COPD, OSA, high altitude

›EPO-secreting tumors: renal cell carcinoma, hepatocellular carcinoma

›Elevated EPO level distinguishes from PV (PV has low or normal EPO)

›Relative polycythemia — Gaisböck syndrome

›Dehydration or diuretic use

›Normal red cell mass; elevated hematocrit from plasma volume contraction

›Other myeloproliferative neoplasms

›Essential thrombocythemia

›ICD-10 D47.3

›Thrombocytosis predominant; normal or mildly elevated hemoglobin

›Primary myelofibrosis

›ICD-10 D47.4

›Leukoerythroblastic smear, massive splenomegaly, tear-drop cells

›Chronic myeloid leukemia

›BCR-ABL1 positive; differentiates from JAK2-driven MPN

Hyperviscosity mimics

›Waldenström macroglobulinemia

›IgM paraprotein causes serum hyperviscosity

›Monoclonal protein on serum protein electrophoresis

›Bone marrow lymphoplasmacytic infiltration

›Multiple myeloma with hyperviscosity

›Rouleaux formation on smear

›Serum free light chains and protein electrophoresis abnormal

Thrombotic emergency mimics

›Thrombotic thrombocytopenic purpura

05Laboratory Tests/lt52

Core hematology

›Complete blood count with differential

›Hemoglobin and hematocrit

›Critical target hematocrit below 45% per CYTO-PV trial

›Hemoglobin above 185 g/L in males and 165 g/L in females — WHO diagnostic threshold

›Platelet count

›Thrombocytosis common at diagnosis

›Platelets at or above 1000 x 10 to the 9 per L — AvWS and paradoxical bleeding risk

›White blood cell count

›Leukocytosis present in many PV cases

›Leukocytosis and neutrophilia are emerging thrombotic risk factors

›Peripheral blood smear

›Leukoerythroblastic changes

›Tear-drop cells and nucleated red cells — myelofibrosis concern

›Circulating blasts — transformation alert

Molecular and diagnostic labs

›JAK2 V617F mutation

›Sensitivity greater than 95% for PV

›Gold standard molecular test when not previously performed

›JAK2 exon 12 mutation testing if V617F negative but PV strongly suspected

›Allele burden correlation

›Higher JAK2 allele burden associated with greater thrombotic risk

›Erythropoietin level

›Low or normal in PV — distinguishes from secondary erythrocytosis

›Elevated EPO favors secondary erythrocytosis or EPO-secreting tumor

›Send before phlebotomy when diagnosis uncertain

Coagulation and bleeding assessment

›Standard coagulation

06Diagnostic Tests/dt77

Scoring Systems

›Thrombosis risk stratification — primary clinical framework

›High-risk criteria

›Age above 60 years OR prior arterial or venous thrombotic event

›Either factor alone qualifies as high-risk

›Drives cytoreductive therapy initiation recommendation

›Low-risk criteria

›Age under 60 years and no prior thrombosis

›Phlebotomy and aspirin as primary management

›Emerging risk modifiers

›Leukocytosis above 11 x 10 to the 9 per L — independent thrombosis predictor

›JAK2 allele burden — high burden associated with greater risk

›Cardiovascular risk factors compound thrombotic risk at any category

›WHO 2022 diagnostic criteria for PV

›Major criteria

›Hemoglobin above 185 g/L in males or above 165 g/L in females

›Bone marrow biopsy with trilineage hyperplasia and pleomorphic megakaryocytes

›JAK2 V617F or JAK2 exon 12 mutation positive

›Minor criterion

›Subnormal serum EPO level

›Three major criteria or two major plus minor criterion required for diagnosis

›MPN Symptom Assessment Form

›Validated patient-reported symptom burden tool

›Quantifies fatigue, pruritus, night sweats, bone pain, fever, weight loss

›Useful for tracking treatment response to cytoreductive therapy

MRI

›Brain MRI and MRV

›Primary indication — cerebral venous sinus thrombosis

›MRV (MR venography) is modality of choice for CVST

›Sensitivity of MRI for CVST superior to CT, especially in early phase

›Acute ischemic stroke

›Diffusion-weighted imaging identifies early infarction within minutes of onset

›ADC map confirms restricted diffusion in acute infarct

›Contraindications

›Hemodynamically unstable patient — CT first for speed

›Non-MRI-compatible implants

›Abdominal MRI

›Hepatic vein and portal vein assessment

›MRI with gadolinium for Budd-Chiari when ultrasound equivocal

›Superior soft-tissue contrast for hepatic parenchymal assessment

›Spleen size quantification

›MRI volumetric assessment in myelofibrosis transformation surveillance

›CT head

›Acute neurologic presentation

›First-line to exclude hemorrhagic stroke

›Non-contrast CT identifies hemorrhage immediately

›Does not reliably exclude acute ischemic stroke — follow with MRI-DWI

›CT pulmonary angiography

›PE diagnosis

›Sensitivity approximately 83% and specificity approximately 96% for PE

›ACEP Level B recommendation for suspected PE with hemodynamic stability

›Wells score plus D-dimer to pre-stratify before CTA

›CT abdomen and pelvis with contrast

›Splanchnic vein thrombosis

›CT portography or triple-phase liver CT for portal/hepatic vein thrombosis

›Identifies Budd-Chiari syndrome, portal vein thrombosis, mesenteric ischemia

›Ascites, hepatomegaly, and caudate lobe hypertrophy on imaging

›Splenomegaly assessment

›Quantifies spleen volume when transformation suspected

›Splenic infarction in severe hyperviscosity

Ultrasound

›Abdominal Doppler ultrasound

›Portal and hepatic vein patency

›First-line for Budd-Chiari diagnosis — sensitivity approximately 85%

›Absent or reversed flow in hepatic veins — Budd-Chiari

›Thrombus in portal or splenic vein

›Spleen size

›Longitudinal diameter above 13 cm — splenomegaly threshold

›More accurate than clinical palpation; ACEP Level B recommendation for POCUS organ assessment

›Lower extremity venous duplex

›DVT diagnosis

›Compression ultrasound with Doppler for femoral and popliteal veins

›Sensitivity above 94% for proximal DVT

›Extends to calf veins when proximal negative and clinical suspicion high

›Echocardiography

›Right heart strain in suspected PE

›RV dilatation, D-sign, McConnell sign

›Tricuspid regurgitation velocity for pulmonary artery pressure estimate

›Pulmonary hypertension screening

›Chronic hyperviscosity and thromboembolism can cause secondary pulmonary hypertension

07Disposition/dispo39

Admission and ICU criteria

›ICU indications

›Active major thrombosis

›Acute ischemic stroke with large territory involvement

›Massive PE with hemodynamic compromise

›Mesenteric or portal vein thrombosis with bowel ischemia

›Major hemorrhage

›Hemodynamic instability from GI or mucocutaneous bleeding

›Active GI variceal bleeding in portal hypertension

›Hyperviscosity with altered consciousness

›Urgent phlebotomy required

›Neurologic decline requires monitored setting

›General admission indications

›Confirmed symptomatic thrombosis requiring parenteral anticoagulation

›DVT, PE, splanchnic vein thrombosis

›Hematocrit requiring serial phlebotomy to control

›Markedly elevated hematocrit with vasomotor symptoms

›Cytoreductive therapy initiation with high-risk features

›Hydroxyurea initiation in high-risk patients

›Transformation concern

›New cytopenias, constitutional symptoms — bone marrow workup inpatient

Discharge criteria

›Safe discharge parameters

›Hematocrit below 45% confirmed

›Vasomotor symptoms resolved

›No acute thrombotic or hemorrhagic event

›Stable outpatient anticoagulation plan established

›DOAC or warfarin with clear monitoring plan

08Treatment/t96

Therapeutic phlebotomy

›Emergency phlebotomy protocol

›Indication

›Hematocrit above 45% with symptoms

›Hematocrit above 52% regardless of symptoms — urgent

›Technique

›Remove 400 to 500 mL whole blood per session

›Frequency: every 1 to 3 days until hematocrit below 45%

›Replace volume with 250 to 500 mL normal saline in elderly or cardiovascular comorbidity

›Target and monitoring

›Hematocrit below 45% — CYTO-PV trial demonstrated 3-fold reduction in cardiovascular death and thrombosis

›Check CBC 24 hours after each session

›Iron deficiency is an expected and often therapeutic consequence — do not supplement iron

Cytoreductive therapy

›Hydroxyurea

›Indication

›High-risk PV: age above 60 or prior thrombosis

›Low-risk patients with inadequate phlebotomy response or poor tolerance

›Dosing

›Initial dose 500 mg orally twice daily

›Titrate to 1000 mg orally twice daily based on response

›Adjust to maintain hematocrit below 45%, platelets below 400 x 10 to the 9 per L, and WBC below 10 x 10 to the 9 per L

›Monitoring

›CBC every 2 to 4 weeks during titration

›Ulcers, cytopenias, and leukemia transformation risk with long-term use

›Class I recommendation for high-risk PV (NCCN, ELN guidelines)

›Pegylated interferon alpha-2a

›Indication

›High-risk PV — preferred in younger patients and females of childbearing age

›Hydroxyurea resistant or intolerant patients

›Dosing

›45 to 90 mcg subcutaneously once weekly

›Titrate based on hematologic response

›Advantages

›Does not increase leukemia transformation risk

›May reduce JAK2 allele burden

›Safe in pregnancy after first trimester

›Ruxolitinib

›Indication

›Hydroxyurea resistant or intolerant PV

›Refractory splenomegaly or symptoms

›Dosing

›Initial 10 mg orally twice daily

›Titrate based on response and tolerability

›Maximum 25 mg twice daily

›Adverse effects

›Increased risk of herpes zoster and opportunistic infections

›Non-melanoma skin cancer risk — annual dermatology screening

Antiplatelet therapy

›Aspirin

›Indication

›All PV patients without contraindication — Class I recommendation

›Reduces thrombotic risk including vasomotor symptoms

›Dosing

›81 to 100 mg orally once daily

›Twice daily for refractory erythromelalgia or vasomotor symptoms

›Contraindications and cautions

›Withhold during active bleeding until hemorrhage controlled

›Use with caution when platelets at or above 1000 x 10 to the 9 per L — AvWS risk

›VWF ristocetin cofactor activity below 30% — hold aspirin

Anticoagulation for thrombosis

›Initial anticoagulation

›Low molecular weight heparin

›Enoxaparin 1 mg/kg subcutaneously every 12 hours — therapeutic dose

›Renally adjust: 1 mg/kg subcutaneously once daily if creatinine clearance below 30 mL per minute

›Preferred in acute thrombosis bridging and pregnancy

›Unfractionated heparin

›IV heparin infusion for massive PE or hemodynamic instability

›Weight-based protocol: 80 units/kg IV bolus then 18 units/kg per hour infusion

›aPTT target 60 to 100 seconds

›Long-term anticoagulation

›Direct oral anticoagulants

›Rivaroxaban 15 mg orally twice daily with food for first 21 days

›Then 20 mg orally once daily with evening meal

›Avoid in pregnancy and severe renal impairment (CrCl below 30)

›Warfarin

›INR target 2.0 to 3.0 for venous thrombosis

›INR target 2.5 to 3.5 for recurrent arterial thrombosis

›Bridge with LMWH until therapeutic INR achieved

›Duration

›Indefinite anticoagulation for splanchnic vein thrombosis in PV — thrombosis is disease-related

›Minimum 3 months for provoked VTE; individualize based on recurrence risk

Symptom management

›Pruritus management

›First-line

›Phlebotomy and hematocrit control often reduces pruritus

›Aspirin 81 to 100 mg orally daily

›Second-line

›Antihistamines — limited efficacy but commonly tried

›Paroxetine 20 mg orally daily — serotonin reuptake inhibition reduces histamine-mediated pruritus

›Ruxolitinib for refractory pruritus in cytoreduction-resistant patients

›Erythromelalgia

›Aspirin — highly effective

›81 to 100 mg orally daily

›Response typically within 1 to 2 days

›Avoidance of heat exposure

›Cool water immersion for acute episodes

›Hyperuricemia and gout

›Allopurinol

›300 mg orally daily for asymptomatic hyperuricemia during cytoreductive therapy

›Continue during phlebotomy and hydroxyurea initiation

09Special Populations/sp68

Pregnancy

›Pregnancy-specific risks

›PV in pregnancy carries high risk of adverse outcomes

›First-trimester miscarriage rate up to 35%

›Placental thrombosis, fetal growth restriction, preeclampsia

›Maternal thrombosis and hemorrhage risk both elevated

›Risk stratification

›All pregnant PV patients classified as high-risk

›Multidisciplinary management: hematology plus maternal-fetal medicine

›Hematocrit targets in pregnancy

›Maintain hematocrit below 45%

›Therapeutic phlebotomy remains first-line — safe in pregnancy

›More frequent monitoring: CBC every 4 to 6 weeks

›Anticoagulation in pregnancy

›LMWH is preferred anticoagulant throughout pregnancy

›Enoxaparin 1 mg/kg subcutaneously every 12 hours — therapeutic

›Prophylactic LMWH for all PV pregnancies throughout gestation and 6 weeks postpartum

›DOACs contraindicated in pregnancy — cross placenta

›Warfarin contraindicated in first trimester — teratogenic

›Cytoreductive therapy in pregnancy

›Hydroxyurea — contraindicated in pregnancy

›Teratogenic; discontinue before conception

›Pegylated interferon alpha-2a — preferred cytoreduction in pregnancy

›Safe after first trimester

›Does not cross placenta significantly

›Low-dose aspirin

›Continue throughout pregnancy unless bleeding occurs

›81 mg orally daily

Geriatric

›Age-related risk elevation

›Age above 60 years is a high-risk criterion for thrombosis

›Cytoreductive therapy required in all high-risk elderly patients

›Hydroxyurea first-line given tolerability profile

›Cardiovascular comorbidity concentration

›Higher background hypertension, diabetes, and atrial fibrillation burden

›Each comorbidity multiplies thrombotic risk beyond disease risk alone

›Phlebotomy in elderly patients

›Volume replacement essential

›250 to 500 mL normal saline after each phlebotomy session

›Orthostatic hypotension risk higher in elderly

›Smaller phlebotomy volumes may be required: 200 to 300 mL in frail patients

›Drug considerations

›Renal dosing adjustments

›Hydroxyurea: dose reduction with CrCl below 60 mL per minute

›DOAC selection: prefer apixaban in older adults for lower bleeding risk

›Enoxaparin: monitor anti-Xa level in CrCl below 30 mL per minute

›Falls and bleeding risk

›Anticoagulation benefit-risk assessment individualized

›High fall risk does not automatically contraindicate anticoagulation in PV — thrombosis risk is disease-driven

Pediatrics

›Pediatric PV characteristics

›PV in children is rare — consider secondary causes first

›Congenital erythrocytosis from EPO receptor mutations

›High-altitude adaptation, cardiac shunt, carboxyhemoglobin

›JAK2 V617F testing in children with true erythrocytosis

›PV confirmed by WHO criteria requires pediatric hematology involvement

›Management in confirmed pediatric PV

›Phlebotomy

›Weight-based volume: 5 to 7 mL/kg per session

›Replace volume with normal saline

›Aspirin

›Low-dose aspirin if no contraindication

›1 to 2 mg/kg per day orally, maximum 100 mg per day

›Cytoreductive therapy

›Hydroxyurea: 15 to 20 mg/kg per day orally; titrate to response

›Interferon alpha preferred in young patients over hydroxyurea for long-term use

›Pediatric hematology-oncology co-management essential

›Special considerations

›Growth and development monitoring during hydroxyurea therapy

›CBC and hepatic function every 3 months

›Avoid erythropoiesis-stimulating agents and iron supplementation

10Background/b67

Epidemiology

›Incidence and prevalence

›Incidence approximately 0.4 to 2.8 per 100,000 persons per year in Western countries

›Prevalence approximately 22 per 100,000 persons

›JAK2 V617F discovery in 2005 significantly improved diagnostic accuracy

›Age and sex distribution

›Median age at diagnosis 61 years

›Slight male predominance with male-to-female ratio approximately 1.2 to 1

›Rare under age 40; increasing incidence with age

›Familial risk

›Approximately 5-fold increased risk of PV among first-degree relatives

›Germline JAK2 46/1 haplotype (GGCC) predisposes to acquired JAK2 mutation

›Thrombosis and mortality burden

›Thrombosis is the leading cause of morbidity and mortality in PV

›Arterial thrombosis: stroke and TIA most common; MI in approximately 8.3%

›Venous thrombosis: DVT, PE, splanchnic vein thrombosis

›Cumulative 10-year thrombosis risk approximately 25% without treatment

›Transformation risk

›Post-PV myelofibrosis in approximately 10 to 20% within 20 years

›Blast phase transformation in approximately 2 to 3% within 20 years

›Median survival approximately 14 to 19 years in modern series

Pathophysiology

›JAK2 V617F mutation mechanism

›Point mutation in exon 14 of the JAK2 gene

›Results in constitutive activation of the JAK-STAT signaling pathway

›Causes cytokine-independent proliferation of erythroid, myeloid, and megakaryocyte progenitors

›Present in above 95% of PV cases; JAK2 exon 12 in remaining 5%

›Panmyelosis

›Trilineage hyperplasia in bone marrow

›Pleomorphic megakaryocytes — distinctive PV histologic feature

›Erythrocytosis drives hyperviscosity

›Hyperviscosity and thrombosis mechanism

›Hematocrit and blood viscosity relationship

›Exponential increase in blood viscosity as hematocrit exceeds 45%

›High hematocrit reduces shear stress and promotes platelet-endothelium interaction

›Platelet activation and endothelial dysfunction compound risk

›Acquired von Willebrand syndrome mechanism

›Extreme thrombocytosis adsorbs high-molecular-weight VWF multimers onto platelet surface

›Proteolytic cleavage reduces functional VWF

›Paradoxical bleeding despite elevated platelet count

›Aquagenic pruritus mechanism

›Histamine release from increased basophil and mast cell degranulation

›Water contact triggers prostaglandin D2 release

›Serotonin pathway involvement — basis for SSRI efficacy

Therapeutic Considerations

›CYTO-PV trial evidence

›Randomized trial demonstrating hematocrit below 45% reduces cardiovascular events

›Hematocrit 45 to 50% versus below 45% — rate of cardiovascular death and major thrombosis 10.9% vs 4.4%

›Establishes hematocrit below 45% as mandatory therapeutic target

›Class I recommendation based on CYTO-PV data and ELN guidelines

›Phlebotomy versus cytoreductive strategy

›Low-risk patients: phlebotomy plus aspirin — preferred initial strategy

›Avoids chemotherapy exposure in younger patients

›Maintain hematocrit below 45% with phlebotomy

›High-risk patients: cytoreduction plus phlebotomy plus aspirin mandatory

›Hydroxyurea first-line for high-risk — PROUD-PV and CONTINUATION-PV trial support

›Hydroxyurea resistance or intolerance — ruxolitinib or interferon alpha

›Anticoagulation strategy in splanchnic vein thrombosis

›Indefinite anticoagulation recommended for all PV-related splanchnic thrombosis

›High recurrence risk without ongoing anticoagulation

›DOACs increasingly used; warfarin historically standard

›Early anticoagulation plus cytoreduction improves recanalization rates

›Secondary prevention principles

›Cardiovascular risk factor modification

›Blood pressure target below 130/80 mmHg

›Statin therapy for hyperlipidemia

›Smoking cessation — reduces both secondary erythrocytosis confounding and thrombosis risk

›Iron supplementation avoidance

›Iron deficiency from phlebotomy is a therapeutic consequence

›Iron repletion reverses phlebotomy benefit and causes rapid hematocrit rebound

11Patient Discharge Instructions/pdi32

copy discharge instructions

›Polycythemia vera home care

›Take all medications exactly as prescribed

›Aspirin daily as directed

›Hydroxyurea or other cytoreductive medication without missing doses

›Blood thinners as prescribed — take at same time each day

›Stay well hydrated

›At least 8 glasses of water per day

›Dehydration makes your blood thicker and increases clot risk

›Attend all scheduled phlebotomy (blood removal) appointments

›Do not miss or delay phlebotomy without contacting your hematologist

›Dietary guidance

›Avoid iron-rich supplements and iron-fortified foods unless specifically advised

›Limit purine-rich foods if you have had gout: red meat, organ meats, shellfish, alcohol

›Return to emergency department immediately for

›Sudden weakness, numbness, or paralysis on one side of the body

›Sudden speech difficulty or confusion

›Sudden loss of vision in one or both eyes

›Severe sudden headache unlike any previous headache

›Chest pain, shortness of breath, or sudden worsening of breathing

›Severe abdominal pain

›Leg swelling, redness, or pain suggesting a blood clot

›Unusual or significant bleeding: heavy nosebleeds, vomiting blood, black stools

›High fever or chills suggesting infection

›Follow-up instructions

›Hematologist appointment within 1 to 2 weeks — confirm before leaving hospital

›CBC blood test at follow-up to check blood counts

›Primary care physician within 2 to 4 weeks for cardiovascular risk factor review

12References/r26

Guidelines and key sources

›Primary society guidelines

›European LeukemiaNet (ELN) 2018 recommendations for polycythemia vera management

›Defines high-risk and low-risk categories; endorses hematocrit target below 45%

›Hydroxyurea first-line cytoreduction for high-risk patients

›NCCN Clinical Practice Guidelines in Oncology: Myeloproliferative Neoplasms

›Annual updates; provides algorithmic risk stratification and treatment pathways

›British Committee for Standards in Haematology (BCSH) PV guidelines

›Phlebotomy protocols and aspirin recommendations

›Landmark trials

›CYTO-PV trial

›Marchioli R et al, NEJM 2013

›Hematocrit below 45% reduces cardiovascular death and major thrombosis rate from 10.9% to 4.4%

›PROUD-PV and CONTINUATION-PV trials

›Ropeginterferon alfa-2b versus hydroxyurea in PV

›Non-inferior response rates; favorable molecular response with interferon

›RESPONSE trial

›Ruxolitinib versus best available therapy for hydroxyurea-resistant or intolerant PV

›Superior hematocrit control and spleen volume reduction

›Key evidence sources

›Barbui T et al — thrombosis risk and leukocytosis as emerging factor in PV

›Tefferi A et al — survival and outcome studies in myeloproliferative neoplasms

›WHO Classification of Haematolymphoid Tumours 2022 — diagnostic criteria update

›Coding standards

›ICD-10 D45 — polycythemia vera

›ICD-10 D75.1 — secondary polycythemia

›SNOMED CT 109992005 — polycythemia vera disorder concept

Learn More: Polycythemia Vera (Crisis)→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.